DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Elan Corporation PLC 

Treasury Building
Lower Grand Canal Street
Dublin    2  Ireland
Phone: 353-1-709-4000 Fax: 353-1-709-4700


SEARCH JOBS






Collaborations

Athersys, Inc.  A joint venture to develop and commercialize a specific therapeutic protein. Athersys is contributing the protein production capabilities of its RAGE technology and Elan is contributing a proprietary drug delivery technology.

Norseman, Inc.  Strategic Partnership - Web based Digital Document Delivery software

Neurome, Inc.  The research partnership with Elan has an initial term of 3 years and may generate up to $4 million in service revenue for Neurome, together with shared ownership of the diagnostic and therapeutic applications of the genes, circuits and mechanisms identified in the research. The partnership will utilize Neurome's technologies to analyze a mouse model of Alzheimer's Disease with the goal of identifying and exploiting molecules and pathways relevant to diagnosis and treatment of the disease. The partnership will analyze Elan's proprietary mouse model of amyloid deposition in an attempt to answer a variety of scientific questions regarding amyloid deposition.

Biogen Idec, Inc. (Massachusetts)  (crohn's & MS)

Digital Gene Technologies  Alzheimer's Disease, Parkinson's Disease, novel mechanisms for drug delivery

RxKinetix, Inc.  Joint venture for the treatment of oral mucositis

NewBiotics, Inc. 

Agenus (Formerly known as Antigenics Inc. - New York) 

Biogen Idec, Inc. (North Carolina)  (crohn's & MS)





 Company News
Royalty Pharma Increases Offer for Elan Corporation PLC (ELN) to $12.50 Per Share in All Cash 5/21/2013 9:42:00 AM    More...
Royalty Pharma Raises Elan Corporation PLC (ELN) Bid to $12.50 a Share in Cash 5/21/2013 7:35:56 AM    More...
Elan Corporation PLC (ELN)’s Response to Royalty Pharma Announcement 5/20/2013 2:10:29 PM    More...
Elan Corporation PLC (ELN) Spends $380 Million to Repel Royalty Pharma Bid, Eyes More Deals With $1 Billion Warchest 5/20/2013 7:33:55 AM    More...
Elan Corporation PLC (ELN) Announces Publication of Response Document 5/16/2013 11:40:01 AM    More...
Elan Corporation PLC (ELN) Bets $1 Billion on Theravance, Inc. (THRX) Drugs; Move to Spurn Its Hostile Suitor? 5/13/2013 6:40:50 AM    More...
Royalty Pharma Warns of Job Cuts if Elan Corporation PLC (ELN) Bid Accepted 5/6/2013 7:54:05 AM    More...
Royalty Pharma Submits Formal Cash Offer for Elan Corporation PLC (ELN) ("Elan") 5/2/2013 9:53:42 AM    More...
Elan Corporation PLC (ELN) Reports First Quarter 2013 Financial Results 4/24/2013 7:14:57 AM    More...
Elan Corporation PLC (ELN) Board Rejects Royalty Pharma Takeover Bid 4/22/2013 8:27:35 AM    More...
12345678910...